Potent inhibition of human apurinic/apyrimidinic endonuclease 1 by arylstibonic acids.
Human apurinic/apyrimidinic endonuclease (Ape1) plays an important role by processing the >10,000 highly toxic abasic sites generated in the genome of each cell every day. Ape1 has recently emerged as a target for inhibition, in that its overexpression in tumors has been linked with poor response to both radiation and chemotherapy and lower overall patient survival. Inhibition of Ape1 using siRNA or the expression of a dominant-negative form of the protein has been shown to sensitize cells to DNA-damaging agents, including various chemotherapeutic agents. However, potent small-molecule inhibitors of Ape1 remain to be found. To this end, we screened Ape1 against the NCI Diversity Set of small molecules and discovered aromatic nitroso, carboxylate, sulfonamide, and arylstibonic acid compounds with micromolar affinities for the protein. A further screen of a 37-compound arylstibonic acid sublibrary identified ligands with IC(50) values in the range of 4 to 300 nM. The negatively charged stibonic acids act by a partial-mixed mode and probably serve as DNA phosphate mimics. These compounds provide a useful scaffold for development of chemotherapeutic agents against Ape1.
The Johns Hopkins University School of Medicine, 725 North Wolfe Street, Baltimore MD 21205-2185, USA.
Lauren A
LA
Seiple
John H
JH
Cardellina
Rhone
R
Akee
James T
JT
Stivers
D000965:Antimony / Q000737:chemistry / Q000494:pharmacology*; D000970:Antineoplastic Agents / Q000494:pharmacology; D045744:Cell Line, Tumor; D004247:DNA / Q000032:analysis / Q000378:metabolism; D043603:DNA-(Apurinic or Apyrimidinic Site) Lyase / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000302:isolation & purification; D004720:Endonucleases / Q000037:antagonists & inhibitors*; D006801:Humans; D020128:Inhibitory Concentration 50; D007700:Kinetics; D008024:Ligands; D008956:Models, Chemical; D012516:Osteosarcoma / Q000188:drug therapy / Q000201:enzymology / Q000235:genetics / Q000473:pathology; D011994:Recombinant Proteins / Q000037:antagonists & inhibitors / Q000302:isolation & purification; D055672:Static Electricity; D013329:Structure-Activity Relationship; D013379:Substrate Specificity
D000970:Antineoplastic Agents; D008024:Ligands; D011994:Recombinant Proteins; D004247:DNA; D000965:Antimony; D004720:Endonucleases; D043603:DNA-(Apurinic or Apyrimidinic Site) Lyase